^
BIOMARKER:

PTEN mutation

i
Other names: PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM
Entrez ID:
Related biomarkers:
PTEN mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive: B - Late Trials
PTEN mutation
Prostate Cancer
bicalutamide
Sensitive: B - Late Trials
PTEN mutation
CRC
panitumumab
Sensitive: B - Late Trials
PTEN mutation
GBM
atezolizumab + GDC-0068
Sensitive: C3 – Early Trials
PTEN mutation
Triple Negative Breast Cancer
pembrolizumab
Resistant: C3 – Early Trials
PTEN mutation
Triple Negative Breast Cancer
atezolizumab
Resistant: C3 – Early Trials
PTEN mutation
Endometrial Cancer
LY3023414
Sensitive: C3 – Early Trials
PTEN mutation
Hormone Receptor Positive Breast Cancer
alpelisib
Resistant: C3 – Early Trials
PTEN mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: C3 – Early Trials
PTEN mutation
CRC
cetuximab
Resistant: C3 – Early Trials
PTEN mutation
Prostate Cancer
abiraterone acetate + GDC-0068
Resistant: C3 – Early Trials
PTEN mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
PTEN mutation
Melanoma
pembrolizumab + GSK2636771
Sensitive: C3 – Early Trials
PTEN mutation
Prostate Cancer
enzalutamide + CC-115
Sensitive: C3 – Early Trials
PTEN mutation
Melanoma
vemurafenib
Resistant: C4 – Case Studies
PTEN mutation
Pancreatic Cancer
MK-2206
Sensitive: C4 – Case Studies
PTEN mutation
GBM
MLN4924
Resistant: D – Preclinical
PTEN mutation
Glioma
MLN4924
Resistant: D – Preclinical
PTEN mutation
Prostate Cancer
dasatinib + AZD8055
Sensitive: D – Preclinical
PTEN mutation
CRC
PARP inhibitor
Resistant: D – Preclinical
PTEN mutation
Breast Cancer
TAK-228
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
AZD6482
Resistant: D – Preclinical
PTEN mutation
Endometrial Cancer
GSK2636771
Resistant: D – Preclinical
PTEN mutation
Endometrial Cancer
GDC-0941
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
RTB101
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
A66
Resistant: D – Preclinical
PTEN mutation
Endometrial Cancer
A66 + AZD6482
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
GSK2636771 + A66
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
TGX-221
Sensitive: D – Preclinical
PTEN mutation
Endometrial Cancer
temsirolimus
Sensitive: D – Preclinical
PTEN mutation
Ovarian Cancer
AMG479
Resistant: D – Preclinical
PTEN mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
PTEN mutation
Gastric Cancer
alpelisib
Sensitive: D – Preclinical
PTEN mutation
SCCHN
GDC-0032
Resistant: D – Preclinical
PTEN mutation
Endometrial Cancer
GDC-0068
Sensitive: D – Preclinical
PTEN mutation
Melanoma
PD1 inhibitor
Sensitive: D – Preclinical